Medipal stock was last at JPY 2,956.5 as Q1 revenue rose

Published on 10/07/2026 at 06:40 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Medipal stock has a JPY 3,145 average 12-month target from four analysts, with a JPY 2,900 to JPY 3,600 range. Q1 revenue reached JPY 989,503 million on August 5.

Medipal, JP3268950007, Illustration mit AI erstellt.

Medipal stock was last at JPY 2,956.5 on the Tokyo Stock Exchange on October 6, 2026, up 0.52 percent on the session. The company is now balancing stronger quarterly revenue with a management transition that took effect on October 1.

Quarterly revenue reaches JPY 989,503 million

Medipal reported fiscal Q1 2027 revenue of JPY 989,503 million and net income of JPY 13,646 million. According to Investing.com, the quarter ended with earnings per share of JPY 66.7, while the latest announcement was dated August 5, 2026.

Revenue increased 9.25 percent from JPY 905,687 million in the prior quarter to JPY 989,503 million. Net income rose from JPY 5,120 million to JPY 13,646 million over the same comparison, giving investors a clearer measure of operating momentum than the modest October 6 share-price change.

Leadership changed on October 1

Medipal's governance structure changed on October 1, 2026, when Kuniharu Imagawa became representative director and president. Japan IR published the underlying notice on September 8, 2026.

Shuichi Watanabe moved to representative director and chairman, while the company also reshaped responsibilities among its directors. The change places the pharmaceuticals business inside a three-person leadership structure as Medipal prepares for the next stage of its medium-term plan.

Consensus points to JPY 3,145

The 12-month analyst consensus is Buy, based on one Buy rating, three Holds and zero Sells from four analysts. Investing.com lists an average target of JPY 3,145, with a high of JPY 3,600 and a low of JPY 2,900.

The average target stands JPY 188.5 above the October 6 price, while the target range shows a meaningful spread in expectations. Separately, Yahoo! Finance reported that a US brokerage raised its rating on September 18, 2026, from Underperform to Buy and lifted its target from JPY 2,820 to JPY 3,600.

Stock stays below JPY 3,000

Medipal stock remained below the JPY 3,000 threshold on October 6, 2026, despite the quarterly revenue increase and the leadership change. For investors, the next assessment point is whether the new management structure can convert revenue growth into sustained earnings improvement.